title: Molecular targets for treatment of Barrett's esophagus.
abstract: SUMMARY. Esophageal cancer is one of the most deadly forms of gastrointestinal cancer with a mortality rate exceeding 90%. The major risk factors for esophageal adenocarcinoma are gastroesophageal reflux disease (GERD) and its sequela, Barrett's esophagus. GERD commonly leads to esophagitis. In a minority of patients however, ongoing GERD leads to replacement of esophageal squamous mucosa with metaplastic, intestinal-type Barrett's mucosa. In the setting of continued peptic injury, Barrett's mucosa can give rise to esophageal adenocarcinoma. Despite the widespread use of potent acid suppressive therapies for patients with GERD, the incidence of esophageal adenocarcinoma, among white men in the USA, the UK and Europe has continued to rise. Cancers in Barrett's esophagus arise through a sequence of genetic events that endow the cells with six essential physiologic hallmarks of cancer as described by Hanahan and Weinberg in 2000. These cancer hallmarks include the ability to proliferate without exogenous stimulation, to resist growth-inhibitory signals, to avoid triggering the programmed death mechanism (apoptosis), to resist cell senescence, to develop new vascular supplies (angiogenesis), and to invade and metastasize. While the acquisition of these essential attributes is not specific to the neoplastic progression of Barrett's esophagus, this review will focus on the genetic alterations that occur in Barrett's cells that contribute to the acquisition of each of the hallmarks. Moreover, potential diagnostic and therapeutic strategies for Barrett's patients aimed at each of these cancer hallmarks will be reviewed.
authors.affiliation: Department of Medicine, Dallas VA Medical Center and University of Texas Southwestern Medical School, Dallas 75216, USA.
authors.forename: L A
authors.initials: LA
authors.lastname: Feagins
authors.forename: R F
authors.initials: RF
authors.lastname: Souza
mesh_terms: D000230:Adenocarcinoma / Q000209:etiology / Q000235:genetics* / Q000473:pathology / Q000503:physiopathology; D017209:Apoptosis / Q000502:physiology; D001471:Barrett Esophagus / Q000209:etiology / Q000235:genetics* / Q000503:physiopathology*; D002453:Cell Cycle; D016922:Cellular Senescence / Q000502:physiology; D043171:Chromosomal Instability; D018450:Disease Progression; D004938:Esophageal Neoplasms / Q000209:etiology / Q000235:genetics* / Q000473:pathology / Q000503:physiopathology; D005764:Gastroesophageal Reflux / Q000150:complications; D006131:Growth Inhibitors / Q000502:physiology; D006801:Humans; D009385:Neoplastic Processes; D009389:Neovascularization, Pathologic / Q000503:physiopathology
chemical_list: D006131:Growth Inhibitors